Prudential Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.25M Sell
62,875
-10,370
-14% -$528K ﹤0.01% 1102
2025
Q4
$3.64M Sell
73,245
-34,353
-32% -$1.67M ﹤0.01% 1044
2025
Q3
$5.14M Buy
107,598
+5,480
+5% +$221K 0.01% 929
2025
Q2
$3.62M Buy
102,118
+11,035
+12% +$354K ﹤0.01% 1091
2025
Q1
$3.24M Buy
91,083
+24,350
+36% +$863K ﹤0.01% 1048
2024
Q4
$2.37M Buy
66,733
+8,352
+14% +$294K ﹤0.01% 1223
2024
Q3
$1.82M Sell
58,381
-1,325
-2% -$41.4K ﹤0.01% 1548
2024
Q2
$1.6M Sell
59,706
-2,124
-3% -$61.6K ﹤0.01% 1551
2024
Q1
$2.11M Sell
61,830
-1,814
-3% -$54K ﹤0.01% 1422
2023
Q4
$1.84M Sell
63,644
-1,405
-2% -$37.3K ﹤0.01% 1488
2023
Q3
$1.79M Sell
65,049
-3,285
-5% -$100K ﹤0.01% 1447
2023
Q2
$2.05M Buy
68,334
+14,505
+27% +$508K ﹤0.01% 1383
2023
Q1
$1.95M Sell
53,829
-1,574
-3% -$60.5K ﹤0.01% 1361
2022
Q4
$1.98M Sell
55,403
-75
-0.1% -$2.61K ﹤0.01% 1315
2022
Q3
$1.85M Sell
55,478
-3,971
-7% -$129K ﹤0.01% 1374
2022
Q2
$1.7M Sell
59,449
-891
-1% -$25.5K ﹤0.01% 1483
2022
Q1
$1.95M Sell
60,340
-25,487
-30% -$781K ﹤0.01% 1507
2021
Q4
$2.51M Sell
85,827
-93,420
-52% -$2.83M ﹤0.01% 1404
2021
Q3
$4.89M Buy
179,247
+74,200
+71% +$1.99M 0.01% 998
2021
Q2
$3.23M Buy
105,047
+12,952
+14% +$397K ﹤0.01% 1245
2021
Q1
$2.41M Sell
92,095
-422,358
-82% -$11.8M ﹤0.01% 1364
2020
Q4
$12.9M Sell
514,453
-137,769
-21% -$2.97M 0.02% 637
2020
Q3
$13.6M Buy
652,222
+34,366
+6% +$780K 0.03% 541
2020
Q2
$14.7M Buy
617,856
+230,596
+60% +$5.09M 0.03% 544
2020
Q1
$6.97M Sell
387,260
-145,571
-27% -$3.06M 0.02% 785
2019
Q4
$12.6M Buy
532,831
+217,408
+69% +$5.28M 0.02% 762
2019
Q3
$8.67M Buy
315,423
+226,744
+256% +$6.72M 0.01% 894
2019
Q2
$2.94M Sell
88,679
-36,773
-29% -$1.26M ﹤0.01% 1402
2019
Q1
$4.4M Buy
125,452
+1,502
+1% +$55.9K 0.01% 1190
2018
Q4
$4.12M Sell
123,950
-2,050
-2% -$88.2K 0.01% 1176
2018
Q3
$6.34M Sell
126,000
-302,458
-71% -$14.9M 0.01% 1084
2018
Q2
$25.6M Buy
428,458
+27,880
+7% +$1.44M 0.04% 523
2018
Q1
$18.3M Buy
400,578
+3,833
+1% +$160K 0.03% 640
2017
Q4
$15.8M Sell
396,745
-8,225
-2% -$325K 0.02% 736
2017
Q3
$16.2M Sell
404,970
-32,170
-7% -$1.39M 0.02% 713
2017
Q2
$18.8M Buy
437,140
+211,950
+94% +$7.54M 0.03% 631
2017
Q1
$7.05M Sell
225,190
-48,409
-18% -$1.3M 0.01% 986
2016
Q4
$6.91M Buy
273,599
+18,653
+7% +$417K 0.01% 986
2016
Q3
$6.3M Buy
254,946
+57,290
+29% +$1.3M 0.01% 978
2016
Q2
$4.03M Buy
197,656
+104,140
+111% +$1.85M 0.01% 1223
2016
Q1
$1.43M Sell
93,516
-24,592
-21% -$321K ﹤0.01% 1690
2015
Q4
$1.59M Buy
118,108
+3,457
+3% +$53.5K ﹤0.01% 1607
2015
Q3
$1.61M Sell
114,651
-64,000
-36% -$1.19M ﹤0.01% 1556
2015
Q2
$3.03M Buy
178,651
+165,651
+1,274% +$2.36M 0.01% 1353
2015
Q1
$157K Buy
+13,000
New +$123K ﹤0.01% 2160

Other funds holding SUPN

Prudential Financial's SUPN Position: Q1 2026 in Review

Prudential Financial reduced its Supernus Pharmaceuticals (SUPN) stake by 14% in Q1 2026, selling an estimated $528K and leaving 62,875 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1102.

Prudential Financial first reported a position in SUPN in Q1 2015 and has held it in 45 quarters since. The position peaked at $25.6M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Prudential Financial held 62,875 shares of Supernus Pharmaceuticals worth $3.25M as of Q1 2026.
  • Prudential Financial sold 10,370 Supernus Pharmaceuticals shares in Q1 2026, an estimated $528K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1102 holding.
  • Prudential Financial first reported a position in Supernus Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
  • Prudential Financial's Supernus Pharmaceuticals position peaked at $25.6M in Q2 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.